Abbott's troponin test for Architect systems:
This article was originally published in Clinica
Executive Summary
Abbott Laboratories has received US FDA 510(k) clearance to run a test for the cardiac marker troponin I on its Architect line of immunoassay and immunochemistry analysers, the i2000SR and ci8200, respectively. The test marks the second assay in Abbott's acute cardiac panel for the Architect platform, says the Abbott Park, Illinois firm, which is developing additional cardiac assays. It is already available in major markets outside the US. The company added that based on the American College of Cardiology's new criteria for diagnosing heart attack, troponin has become the gold standard in diagnostic testing.